198 related articles for article (PubMed ID: 38014060)
1. Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML.
Lima MCP; Hornsby BD; Lim CS; Cheatham TE
bioRxiv; 2023 Nov; ():. PubMed ID: 38014060
[TBL] [Abstract][Full Text] [Related]
2. Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML.
Lima MCP; Hornsby BD; Lim CS; Cheatham TE
J Phys Chem B; 2024 Jul; ():. PubMed ID: 38951498
[TBL] [Abstract][Full Text] [Related]
3. Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
Cornillie SP; Bruno BJ; Lim CS; Cheatham TE
J Phys Chem B; 2018 Apr; 122(14):3864-3875. PubMed ID: 29519125
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
Bruno BJ; Lim CS
Mol Pharm; 2015 May; 12(5):1412-21. PubMed ID: 25858426
[TBL] [Abstract][Full Text] [Related]
5. Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire.
Liu Y; Zhang M; Jang H; Nussinov R
Protein Sci; 2023 Jan; 32(1):e4504. PubMed ID: 36369657
[TBL] [Abstract][Full Text] [Related]
6. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
[TBL] [Abstract][Full Text] [Related]
7. Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
[TBL] [Abstract][Full Text] [Related]
8. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.
Miller GD; Woessner DW; Sirch MJ; Lim CS
Mol Pharm; 2013 Sep; 10(9):3475-83. PubMed ID: 23915432
[TBL] [Abstract][Full Text] [Related]
9. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
10. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
Dixon AS; Constance JE; Tanaka T; Rabbitts TH; Lim CS
Pharm Res; 2012 Apr; 29(4):1098-109. PubMed ID: 22183511
[TBL] [Abstract][Full Text] [Related]
11. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Woessner DW; Lim CS
Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
[TBL] [Abstract][Full Text] [Related]
12. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.
Beissert T; Hundertmark A; Kaburova V; Travaglini L; Mian AA; Nervi C; Ruthardt M
Int J Cancer; 2008 Jun; 122(12):2744-52. PubMed ID: 18366061
[TBL] [Abstract][Full Text] [Related]
14. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Zhang X; Subrahmanyam R; Wong R; Gross AW; Ren R
Mol Cell Biol; 2001 Feb; 21(3):840-53. PubMed ID: 11154271
[TBL] [Abstract][Full Text] [Related]
15. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
[TBL] [Abstract][Full Text] [Related]
16. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
19. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
20. Disruption of Bcr-Abl coiled coil oligomerization by design.
Dixon AS; Pendley SS; Bruno BJ; Woessner DW; Shimpi AA; Cheatham TE; Lim CS
J Biol Chem; 2011 Aug; 286(31):27751-60. PubMed ID: 21659527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
